HighTower Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

HighTower Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26,948	Closed	-$163K	–	2614
2019 Q4	$163K	Buy	26,948 +2,100	+8%	+$12.2K	﹤0.01%	2016
2019 Q3	$88K	Buy	24,848 +12,550	+102%	+$48.4K	﹤0.01%	2182
2019 Q2	$33K	Hold	12,298	–	–	﹤0.01%	2238
2019 Q1	$37K	Sell	12,298 -1,500	-11%	-$3.69K	﹤0.01%	2142
2018 Q4	$21K	Sell	13,798 -700	-5%	-$1.98K	﹤0.01%	2085
2018 Q3	$53K	Buy	14,498 +100	+0.7%	+$298	﹤0.01%	2121
2018 Q2	$41K	Hold	14,398	–	–	﹤0.01%	2078
2018 Q1	$53K	Buy	14,398 +1,098	+8%	+$3.59K	﹤0.01%	2015
2017 Q4	$38K	Buy	+13,300	New	+$48.3K	﹤0.01%	2126

HighTower Advisors's ACHN Position: Q1 2020 in Review

HighTower Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 26,948 shares — an estimated $163K sold.

HighTower Advisors first reported a position in ACHN in Q4 2017 and held it in 9 quarters. The position peaked at $163K in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

HighTower Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
HighTower Advisors sold 26,948 Achillion Pharmaceuticals shares in Q1 2020, an estimated $163K.
HighTower Advisors first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 9 quarters.
HighTower Advisors's Achillion Pharmaceuticals position peaked at $163K in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on HighTower Advisors's 13F filing for Q1 2020, filed 21 May 2020.